abdominal distention (RR = 0.39, 95% CI: 0.26-0.59)
from: Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on Helicobaconstipation (RR = 0.32, 95% CI: 0.18-0.55)
from: Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on HelicobaSpecifically, it reduced the incidence of some gastrointestinal adverse effects and nonspecific adverse effects, including diarrhea (RR = 0.28, 95% CI: 0.22-0.36)
from: Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on Helicobanausea (RR = 0.59, 95% CI: 0.36-0.97)
from: Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on Helicobarash (RR = 0.49, 95% CI: 0.28-0.86)
from: Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on HelicobaThe addition of S. boulardii to traditional therapy significantly improved the H. pylori eradication rate [RR=1.11, 95% confidence interval (CI): 1.08-1.15] and reduced the incidence of total adverse effects (RR=0.49, 95% CI: 0.37-0.66)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradicationabdominal distension (RR=0.49, 95% CI: 0.33-0.72)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradicationHowever, it did not reduce the occurrence of abdominal pain, vomiting, or taste disorders.
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradicationconstipation (RR=0.38, 95% CI: 0.26-0.57)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradicationreduced the incidence of total adverse effects (RR=0.49, 95% CI: 0.37-0.66), diarrhea (RR=0.36, 95% CI: 0.26-0.48)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradicationnausea (RR=0.50, 95% CI: 0.37-0.68)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradicationHowever, it did not reduce the occurrence of abdominal pain, vomiting, or taste disorders.
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradicationHowever, it did not reduce the occurrence of abdominal pain, vomiting, or taste disorders.
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradicationS. boulardii supplementation to bismuth quadruple therapy significantly improved H. pylori eradication rates (RR = 1.08, 95% CI: 1.04-1.12) and reduced the incidence of total adverse effects (RR = 0.53, 95% CI: 0.45-0.62).
from: Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on Helicobaabdominal distention (RR = 0.39, 95% CI: 0.26-0.59)
reduced the incidence of ... abdominal distension (RR=0.49, 95% CI: 0.33-0.72)